Inclusion Criteria:

- Chinese population surgery patients with invasive breast cancer；

- Stage II-III；

- ER positive；

- HER2 negative；

- Ki67≥14%；

- Aged between 18 and 70 years old；

- The maximum diameter of the primary tumor greater than 1cm；

- ECOG score 0-1 points； -Have adequate baseline bone marrow and organ function reserve
: absolute neutrophil count ≥ 1500/mm3, platelet count ≥ 8g/dl; the ≥ 100000/mm3
hemoglobin concentration and serum creatinine ≤ 1.5 times the upper limit of normal ;
aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit
of normal , bilirubin ≤ 1.5 times the upper limit of normal ; left ventricular
ejection fraction ( LVEF ) ≥ 50%

Exclusion Criteria: - Non - Chinese population of patients；

- Non- invasive cancer patients;

- Inflammatory Breast Cancer patients;

- Metastatic breast cancer patients;

- HER2 positive patients;

- Ki67<14% patients;

- No adequateBaseline bone marrow or organ function reserve;

- ECOG PS score ≥ 2 points;

- Younger than 18 years of age or greater than 70 years old;

- Already accepted therapy including chemotherapy , endocrine therapy or targeted
therapy before neoadjuvant treatment;

- HER2-positive patients with left ventricular ejection fraction less than 55 % can not
receiving Herceptin;

- Known allergy of docetaxel , capecitabine , epirubicin , ring phosphonamide .